Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNTA Genenta Science	$4.48 +0.9%	$4.01	$2.79 ▼ $7.28	$81.94M	0.66	14,605 shs	17,518 shs
QTTB Q32 Bio	$1.75 -7.4%	$1.73	$1.38 ▼ $53.79	$21.35M	-0.02	196,507 shs	74,788 shs
STRO Sutro Biopharma	$0.90 +0.2%	$0.79	$0.52 ▼ $5.17	$76.18M	1.77	1.09 million shs	528,290 shs
TCRX TScan Therapeutics	$1.44 -2.4%	$1.38	$1.02 ▼ $9.29	$81.21M	1.06	404,188 shs	443,333 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNTA Genenta Science	-1.25%	-1.95%	+7.42%	+9.51%	+22.03%
QTTB Q32 Bio	+3.28%	+14.55%	+21.54%	-16.74%	-93.25%
STRO Sutro Biopharma	-1.71%	-0.29%	+2.89%	-43.40%	-78.82%
TCRX TScan Therapeutics	+1.38%	+2.08%	-7.55%	-30.00%	-82.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNTA Genenta Science	2.911 of 5 stars	3.5	5.0	0.0	3.0	1.7	0.0
QTTB Q32 Bio	2.391 of 5 stars	3.1	2.0	0.0	2.7	1.7	1.3
STRO Sutro Biopharma	4.2321 of 5 stars	4.1	2.0	4.7	2.1	1.7	0.6
TCRX TScan Therapeutics	3.2823 of 5 stars	4.5	1.0	0.0	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNTA Genenta Science	3.00	Buy	$25.00	458.04% Upside
QTTB Q32 Bio	2.25	Hold	$24.71	1,312.24% Upside
STRO Sutro Biopharma	2.13	Hold	$6.11	577.86% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	443.55% Upside

Current Analyst Ratings Breakdown

Latest QTTB, GNTA, TCRX, and STRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/17/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$12.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/14/2025	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/14/2025	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$8.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Underperform	$11.00 ➝ $1.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.21 per share	N/A
QTTB Q32 Bio	-$6.65M	-3.21	N/A	N/A	$22.47 per share	0.08
STRO Sutro Biopharma	$66.43M	1.15	N/A	N/A	$2.45 per share	0.37
TCRX TScan Therapeutics	$4.42M	18.37	N/A	N/A	$3.15 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNTA Genenta Science	-$12.60M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	-$112.96M	-$4.94	N/A	N/A	N/A	N/A	-146.18%	-54.49%	8/14/2025 (Estimated)
STRO Sutro Biopharma	-$106.79M	-$2.98	N/A	N/A	N/A	-77.01%	-101.89%	-28.69%	8/12/2025 (Estimated)
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)

Latest QTTB, GNTA, TCRX, and STRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/8/2025	Q1 2025	QTTB Q32 Bio	-$1.23	-$0.90	+$0.33	-$0.90	N/A	N/A
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million
3/13/2025	Q4 2024	STRO Sutro Biopharma	-$0.86	-$2.96	-$2.10	-$0.89	$10.44 million	$14.00 million
3/11/2025	Q4 2024	QTTB Q32 Bio	-$1.25	-$1.16	+$0.09	-$1.16	N/A	N/A
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNTA Genenta Science	N/A	9.31	N/A
QTTB Q32 Bio	0.61	6.53	6.53
STRO Sutro Biopharma	N/A	3.09	3.09
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNTA Genenta Science	15.13%
QTTB Q32 Bio	31.32%
STRO Sutro Biopharma	96.99%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
GNTA Genenta Science	28.99%
QTTB Q32 Bio	40.00%
STRO Sutro Biopharma	3.60%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
QTTB Q32 Bio	39	12.20 million	10.22 million	N/A
STRO Sutro Biopharma	240	84.46 million	77.59 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

QTTB, GNTA, TCRX, and STRO Headlines

Recent News About These Companies

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28 at 7:00 AM | globenewswire.com

TScan Therapeutics (NASDAQ:TCRX) & Relay Therapeutics (NASDAQ:RLAY) Head to Head Contrast

May 25, 2025 | americanbankingnews.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

Head-To-Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Twist Bioscience (NASDAQ:TWST)

May 22, 2025 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

May 14, 2025 | marketbeat.com

Equities Analysts Set Expectations for TCRX Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Equities Analysts Cut Earnings Estimates for TCRX

May 11, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TCRX Q1 Earnings

May 10, 2025 | marketbeat.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10, 2025 | nasdaq.com

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

May 9, 2025 | marketbeat.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

May 8, 2025 | marketbeat.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

May 7, 2025 | marketbeat.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

Adage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

April 30, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Best Biotech Stocks to Buy in 2025
By Dan Schmidt | May 13, 2025
View Best Biotech Stocks to Buy in 2025
Costco Stock at $1K: Dominance or Danger Zone?
By Jeffrey Neal Johnson | May 23, 2025
View Costco Stock at $1K: Dominance or Danger Zone?
3 Reasons Salesforce Could Be Back at All-Time Highs by June
By Sam Quirke | May 21, 2025
View 3 Reasons Salesforce Could Be Back at All-Time Highs by June

QTTB, GNTA, TCRX, and STRO Company Descriptions

Genenta Science NASDAQ:GNTA

$4.53 +0.09 (+1.94%)

As of 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Q32 Bio NASDAQ:QTTB

$1.75 -0.14 (-7.41%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 +0.03 (+1.66%)

As of 04:45 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Sutro Biopharma NASDAQ:STRO

$0.90 +0.00 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 +0.02 (+2.00%)

As of 04:57 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

TScan Therapeutics NASDAQ:TCRX

$1.44 -0.04 (-2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.43 -0.01 (-0.35%)

As of 04:04 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time